STUDY | POPULATION | INTERVENTION OR COMPARATOR | OUTCOMES |
---|---|---|---|
Extended DAPT after coronary stent insertion | |||
• ARCTIC-Interruption,2 2014 |
|
|
|
• DAPT,3 2014 |
|
|
|
• DES-LATE,4 2014 |
|
|
|
• OPTIDUAL,5 2016 |
|
|
|
Extended DAPT after MI | |||
• CHARISMA,17,18 2006 |
|
|
|
• PEGASUS-TIMI 54,19 2015 |
|
|
|
ARCTIC-Intervention—Assessment by a double Randomization of a Conventional antiplatelet strategy versus a monitoring-guided strategy for drug-eluting stent implantation and, of Treatment Interruption versus Continuation 1 year after stenting-Interruption, ASA—acetylsalicylic acid, BMS—bare-metal stent, CHARISMA—Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance, CV—cardiovascular, DAPT—dual antiplatelet therapy, DES—drug-eluting stent, DES-LATE—Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event, G1DES—first-generation drug-eluting stent, GUSTO—Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries, HR—hazard ratio, ISTH—International Society on Thrombosis and Hemostasis, MACCE—major adverse cardiovascular and cerebrovascular events, MI—myocardial infarction, NNH—number needed to harm, NNT—number needed to treat, NSTEMI—non–ST-segment elevation MI, OPTIDUAL—OPTImal DUAL antiplatelet therapy, PCI—percutaneous coronary intervention, PEGASUS-TIMI 54—Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54, RR—relative risk, ST—stent thrombosis, STEEPLE—Safety and Efficacy of Enoxaparin in PCI Patients, STEMI—ST-segment elevation MI, TIMI—thrombolysis in myocardial infarction, UA—unstable angina.
↵* Major adverse cardiovascular and cerebrovascular events including death, MI, or stroke.